Key facts, as of
As of October 8, 2026, Humana Inc. (HUM) trades at $396.51, up 34.3% over the past year. Its 52-week range runs from $163.11 to $428.88; the price is 7.5% below that high. It is 30.6% below its all-time high of $571.30, reached in November 2022. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +134.8%, against +312.9% for the S&P 500 (SPY). It sits 34.2% above its 200-day average of $295.38, the usual sign of a long-term uptrend. Its 30-day volatility is 32.0% annualized, which we rate high risk. It has a trailing P/E of 37.5 and a dividend yield of 0.89%.
Cite: Portfolio Terminal, "Humana Inc. (HUM) stock analysis", 2026-10-08. https://portfolio-terminal.com/analyse/hum
Where it trades today
trading 88% of the way up its 52-week range
How the price has moved
How far it is from its record
Humana Inc. (HUM) is 30.6% below its all-time high of $571.30, reached in November 2022. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +134.8%, against +312.9% for the S&P 500 (SPY).
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- HUM trades at 37.5x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- Recent realized volatility is running around 32.0%, above the sector norm of 22.0%, so position sizing matters more than usual.
- Relative performance versus UNH, JNJ, PFE matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- HUM is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in HUM.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for HUM come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for HUM. Last refresh: Oct 8, 2026, 10:10 AM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Humana Inc. does
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and administrative services to arrange health care services for active-duty and retired military personnel and dependents, as well as pharmacy benefit…
What analysts expect
HUM carries a buy consensus from 23 analysts, with an average price target of $430.70 versus $396.51 today (+8.6%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
HUM generated $145.68B in trailing revenue (26.2% year over year), with a 0.9% net margin, and $1.94B of free cash flow, supported by $9.13B of net cash.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $129.66B | — | — | $1.19B | $9.87 | $375.00M |
| 2024 | $117.76B | — | — | $1.21B | $10.01 | $2.39B |
| 2023 | $106.37B | — | — | $2.49B | $20.09 | $2.98B |
| 2022 | $92.87B | — | — | $2.81B | $22.20 | $3.45B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
HUM is in 8 of the 30 ETFs we track. It weighs most in XLV: 0.74% of the fund, holding #30 of 62.
Famous investors who hold it
HUM is in the latest 13F of 1 of the 15 famous investors we follow. George Soros (Soros Fund Management) holds the most of it: 0.16% of the portfolio, position #128 of 261, as of Q2 2026.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
HUM beside the healthcare names it is usually measured against.
What the chart is saying
In an uptrend, pressing toward $416.18 resistance.
uptrend- Price is 2.6% above its 50-day average and 34.2% above its 200-day.
- The 50-day crossed above the 200-day on 2026-06-05 (a “golden cross”).
- RSI at 54 is neither stretched nor washed out.
- The nearest ceiling is $416.18 (+5.0%), the nearest floor $383.04 (-3.4%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is HUM a good investment in 2026?
Humana Inc. trades at a P/E ratio of 37.5, with high volatility (32.0% annualized). The stock is in a consolidation phase.
What is the risk level of HUM?
Based on 30-day volatility of 32.0%, HUM has HIGH risk. Beta of 0.74 indicates lower sensitivity to market movements than average.
Does HUM pay dividends?
Yes, Humana Inc. has a dividend yield of 0.89%.
How far is HUM from its all-time high?
Humana Inc. is 30.6% below its all-time high of $571.30, reached in November 2022. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +134.8%, against +312.9% for the S&P 500 (SPY).
Which ETFs hold HUM?
8 of the 30 popular ETFs we track hold Humana Inc.. The largest weights: XLV (0.74%), JEPI (0.23%), VYM (0.18%), VTV (0.17%) and VOO (0.07%). Measured on each issuer's full holdings file, dated August 31 to September 24, 2026.
How much of VOO is HUM?
0.07%, as of August 31, 2026: HUM is holding #240 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $0.70 in Humana Inc..
Which famous investors own HUM?
George Soros (0.16% of Soros Fund Management's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for HUM?
The average analyst price target for Humana Inc. (HUM) is $430.70 based on 23 analyst estimates, about 8.6% above the current price of $396.51. The published range runs from $280.00 to $515.00.
How much revenue does HUM generate?
Humana Inc. reported $145.68B in trailing twelve-month revenue. Revenue growth is running at 26.2% year over year. Net margin sits at 0.9%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare HUM with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.